Press Announcements > FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease

Press Announcements > FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease

FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease

06/22/2017 05:15 PM EDT

The U.S. Food and Drug Administration today approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients. The subcutaneous route of administration allows for easier at-home self-injection by the patient or caregiver, once proper training is received.